ピルフェニドンは反復抗原暴露により起こる気道過敏性，気道炎症および気道リモデリングを制御する

We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 levels in bronchoalveolar lavage fluid and ovalbumin-specific serum IgE antibody levels were also significantly reduced. Treatment with pirfenidone significantly reduced transforming growth factor-beta1 and platelet-derived growth factor levels in bronchoalveolar lavage fluid. Pirfenidone reduced the expression of transforming growth factor-beta1, the development of goblet cell hyperplasia and subepithelial collagenization, and the increases in contractile elements in the lung. These data indicate that pirfenidone may play an important role in the treatment of asthma and has the potential reduce or prevent airway remodeling

The nutrient sensing signaling pathways in the hematopoietic stem cells and leukemia

The 3rd International Symposium on Carcinogenic Spiral & International Symposium on Tumor Biology in Kanazawa, [DATE]: January 24(Thu)-25(Fri),2013, [Place]:Kanazawa Excel Hotel Tpkyu, Kanazawa, Japan, [Organizers]:Infection/Inflammation-Assisted Acceleration of the Carcinogenic Spiral and its Alteration through Vector Conversion of the Host Response to Tumors / Scientific Research on Innovative Areas, a MEXT Grant-in Aid Projec

Arthroscopic treatment of intra-articular dysplasia epiphysealis hemimelica of the knee

Dysplasia epiphysealis hemimelica, also known as Trevor Fairbank disease, is characterized by asymmetrical osteochondral overgrowth of the epiphyseal cartilage. The clinical presentation of dysplasia epiphysealis hemimelica is wide and variable, depending on the site of the lesion. Herein, we describe the physical examination of a 9-year-old boy with intra-articular dysplasia epiphysealis hemimelica, in whom the symptoms were elicited on “reverse Wilson’s sign”: bending the knee from 70° to 120° against resistance while externally rotating the tibia. Arthroscopic treatment of the intra-articular dysplasia epiphysealis hemimelica of the knee showed good outcome; hence, this modality should be considered for the management of intra-articular dysplasia epiphysealis hemimelica

Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis

Because of the pathological role of IL-6 in rheumatoid arthritis (RA), tocilizumab (TCZ), a humanized anti-IL-6 receptor monoclonal antibody, was expected to improve inflammation and joint destruction of RA. Indeed, randomized clinical trials demonstrated the clinical efficacy of TCZ as monotherapy or combined with methotrexate (MTX) for RA patients with inadequate responses to disease-modifying antirheumatic drugs, MTX or tumor necrosis factor (TNF) inhibitors. Although long-term tolerability for TCZ is superior to that for TNF inhibitors, information regarding the potency of drug free remission of TCZ is limited at present. In terms of its safety profile, the general risk of infection when using TCZ is comparable to that of TNF inhibitors. TCZ has some advantage in RA patients who can not use MTX and are non-responders to TNF inhibitors. In conclusion, TCZ is one of the most prospective next generation biologics for the treatment of RA